WuXi AppTec has announced that has acquired Pharmapace (San Diego, California), a clinical research services company with expertise in providing biometrics services for all phases of clinical trials, regulatory submissions, and post marketing support. Pharmapace will become a wholly owned subsidiary of WuXi Clinical and will continue to focus on growing its core biometrics competences and integrate with WuXi Clinical’s other clinical development services.
Pharmapace, which was founded in 2013, provides a full range of biometrics services for all phases of clinical trials, including clinical and statistical programming, data management, biostatistics, clinical data integration, and medical writing. The acquisition enables WuXi Clinical to expand its biometrics capabilities in the US and Europe. By integrating Pharmapace and WuXi Clinical biometrics teams, WuXi Clinical will be able to provide its customers with efficient and cost-effective biometrics services, the company says.
“This acquisition further enhances WuXi Clinical’s drug development expertise and biometrics capabilities and lays the foundation for the creation of an integrated global biometrics service platform to efficiently and cost-effectively provide customers seamless biometrics services,” says Edward Hu, co-CEO, WuXi AppTec. “Together, we [will be] able to shorten time-to-market of new drugs and to achieve the dream that ‘every drug can be made and every disease can be treated’,” Hu says.
By Michael Ravenscroft
Source: Chemical Week
Lin will become the company’s Chief Transformation and Talent Officer. She will be responsible for Human Resources, Strategy and Business Consulting and drive the accelerated transformation of Bayer.
Johnson Matthey plc (JM; London) has confirmed that its battery cathode materials plant in Konin, Poland, will be powered solely by electricity from renewable sources from day one of production.
Britain’s Oxford University has received a donation of £100 million (112 million euros, $136 million) to research growing resistance to antibiotics, the university announced on Tuesday. The sum, from British chemicals multinational Ineos, is one of the largest donations given to Oxford University in its long history.